| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.JURO.2015.01.086 |
| P698 | PubMed publication ID | 25623737 |
| P50 | author | American Urological Association | Q4745327 |
| P2093 | author name string | Martha M Faraday | |
| Deborah Erickson | |||
| Philip M Hanno | |||
| Robert Moldwin | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1545-1553 | |
| P577 | publication date | 2015-01-23 | |
| P1433 | published in | Journal of Urology | Q15709979 |
| P1476 | title | Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment | |
| P478 | volume | 193 |
| Q49392573 | A Case-Crossover Study of Urological Chronic Pelvic Pain Syndrome Flare Triggers in the MAPP Research Network. |
| Q36599064 | A Feasibility Study to Determine Whether Clinical Contrast Enhanced Magnetic Resonance Imaging can Detect Increased Bladder Permeability in Patients with Interstitial Cystitis |
| Q48176897 | A genome-scale DNA methylation study in women with interstitial cystitis/bladder pain syndrome |
| Q90224636 | A longitudinal analysis of urological chronic pelvic pain syndrome flares in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network |
| Q26773567 | A multidisciplinary approach to the evaluation and management of interstitial cystitis/bladder pain syndrome: an ideal model of care |
| Q37626521 | A prospective randomized controlled multicentre trial comparing intravesical DMSO and chondroïtin sulphate 2% for painful bladder syndrome/interstitial cystitis |
| Q38937743 | A standard for terminology in chronic pelvic pain syndromes: A report from the chronic pelvic pain working group of the international continence society |
| Q64059049 | A survey for ketamine abuse and its relation to the lower urinary tract symptoms in Taiwan |
| Q46556756 | Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice. |
| Q89464176 | Acyloxyacyl hydrolase modulates voiding activity |
| Q48227598 | Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). |
| Q36735590 | Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction? |
| Q54255809 | Alpha-oxoglutarate inhibits the proliferation of immortalized normal bladder epithelial cells via an epigenetic switch involving ARID1A. |
| Q93356015 | An Overview of the Pathology and Emerging Treatment Approaches for Interstitial Cystitis/Bladder Pain Syndrome |
| Q34542163 | Anorectal and Pelvic Pain |
| Q38743785 | Anti-vascular endothelial growth factor treatment decreases bladder pain in cyclophosphamide cystitis: a Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network animal model study |
| Q90362239 | Application of Adult and Pluripotent Stem Cells in Interstitial Cystitis/Bladder Pain Syndrome Therapy: Methods and Perspectives |
| Q90641971 | Assessing bladder hyper-permeability biomarkers in vivo using molecularly-targeted MRI |
| Q36219843 | Assessment of colon and bladder crosstalk in an experimental colitis model using contrast-enhanced magnetic resonance imaging |
| Q49325488 | Biomarkers for interstitial cystitis/painful bladder syndrome. |
| Q91830880 | Bladder Hydrodistention Does Not Result in a Significant Change in Bladder Capacity for Interstitial Cystitis/Bladder Pain Syndrome Patients |
| Q90177034 | Bladder Pain Syndome/Interstitial Cystitis due to Pudendal Nerve Compression: Described in 1915-A Reminder for Treating Pelvic Pain a Century Later |
| Q42374948 | Bladder pain in an LL-37 interstitial cystitis and painful bladder syndrome model |
| Q37585440 | Blocking PAR2 Alleviates Bladder Pain and Hyperactivity via TRPA1 Signal |
| Q37375064 | Blocking mammalian target of rapamycin alleviates bladder hyperactivity and pain in rats with cystitis |
| Q26750535 | Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action |
| Q97553638 | CHARACTERIZATION AND PREVALENCE OF FEMALE PELVIC PAIN IN A GENERAL OUTPATIENT UROLOGY POPULATION |
| Q38602766 | Chronic pelvic pain in women: an epidemiological perspective |
| Q52361687 | Clinical Criteria of Central Sensitization in Chronic Pelvic and Perineal Pain (Convergences PP Criteria): Elaboration of a Clinical Evaluation Tool Based on Formal Expert Consensus. |
| Q38824147 | Clinical Efficacy of 1-Year Intensive Systematic Dietary Manipulation as Complementary and Alternative Medicine Therapies on Female Patients With Interstitial Cystitis/Bladder Pain Syndrome. |
| Q89705017 | Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis |
| Q48054557 | Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. |
| Q64332501 | Current best practice management of interstitial cystitis/bladder pain syndrome |
| Q26773527 | Current guidelines in the management of interstitial cystitis |
| Q64911986 | Cystoscopic evaluation and clinical phenotyping in interstitial cystitis/bladder pain syndrome |
| Q45948914 | Development of an interstitial cystitis risk score for bladder permeability. |
| Q64250251 | Diagnosis in a Preclinical Model of Bladder Pain Syndrome Using a Au/ZnO Nanorod-based SERS Substrate |
| Q38755106 | Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: A review |
| Q93150294 | Does repeated hydrodistension with transurethral fulguration for interstitial cystitis with Hunner's lesion cause bladder contraction? |
| Q92024620 | Dysregulation of bladder corticotropin-releasing hormone receptor in the pathogenesis of human interstitial cystitis/bladder pain syndrome |
| Q41467264 | Effect of local estrogen therapy (LET) on urinary and sexual symptoms in premenopausal women with interstitial cystitis/bladder pain syndrome (IC/BPS). |
| Q36006813 | Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis |
| Q52629946 | Elevated Urine Levels of Macrophage Migration Inhibitory Factor in Inflammatory Bladder Conditions: A Potential Biomarker for a Subgroup of Interstitial Cystitis/Bladder Pain Syndrome Patients. |
| Q40059471 | Evaluation of the incidence and risk factors associated with persistent frequency in interstitial cystitis/bladder pain syndrome and the efficacy of antimuscarinic treatment |
| Q36230460 | Evidence for the Role of Mast Cells in Cystitis-Associated Lower Urinary Tract Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study. |
| Q38719945 | Expression profile of urothelial transcription factors in bladder biopsies with interstitial cystitis |
| Q37034776 | F16357, a novel protease-activated receptor 1 antagonist, improves urodynamic parameters in a rat model of interstitial cystitis |
| Q36241186 | Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study |
| Q34546729 | Functional urological disorders: a sensitized defence response in the bladder-gut-brain axis |
| Q48297020 | Histopathological characteristics of interstitial cystitis/bladder pain syndrome without Hunner lesion. |
| Q57136724 | IL-33 mast cell axis is central in LL-37 induced bladder inflammation and pain in a murine interstitial cystitis model |
| Q37624742 | Important role of physicians in addressing psychological aspects of interstitial cystitis/bladder pain syndrome (IC/BPS): a qualitative analysis. |
| Q41488924 | Improved efficacy and in vivo cellular properties of human embryonic stem cell derivative in a preclinical model of bladder pain syndrome |
| Q36451079 | In what type of interstitial cystitis/bladder pain syndrome is DMSO intravesical instillation therapy effective? |
| Q36090760 | Increased Expression of Neuregulin 1 and erbB2 Tyrosine Kinase in the Bladder of Rats With Cyclophosphamide-Induced Interstitial Cystitis |
| Q100523540 | Increased Transient Receptor Potential Melastatin 8 Expression in the development of bladder pain in patients with Interstitial cystitis/Bladder Pain Syndrome |
| Q26773559 | Interstitial cystitis/painful bladder syndrome: diagnostic evaluation and therapeutic response in a private urogynecology unit |
| Q38759710 | Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC). |
| Q64326482 | Is It Possible to Prevent Symptom Recurrence After Transurethral Resection for Hunner Lesion? |
| Q60960062 | Long-Term Relief of Painful Bladder Syndrome by High-Intensity, Low-Frequency Repetitive Transcranial Magnetic Stimulation of the Right and Left Dorsolateral Prefrontal Cortices |
| Q47352326 | Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome |
| Q91223856 | Management of Symptom Flares and Patient-reported Flare Triggers in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)-Findings From One Site of the MAPP Research Network |
| Q90323105 | Menthol, a unique urinary volatile compound, is associated with chronic inflammation in interstitial cystitis |
| Q52659090 | Morbidity rate and medical utilization in interstitial cystitis/painful bladder syndrome. |
| Q64966321 | Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction. |
| Q26774233 | Novel research approaches for interstitial cystitis/bladder pain syndrome: thinking beyond the bladder |
| Q36427293 | PK2/PKR1 Signaling Regulates Bladder Function and Sensation in Rats with Cyclophosphamide-Induced Cystitis |
| Q64253102 | Persistent autonomic dysfunction and bladder sensitivity in primary dysmenorrhea |
| Q52653498 | Preclinical Animal Studies of Intravesical Recombinant Human Proteoglycan 4 as a Novel Potential Therapy for Diseases Resulting From Increased Bladder Permeability. |
| Q90720476 | Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome |
| Q47602992 | Psychosocial co-morbidities in Interstitial Cystitis/Bladder Pain syndrome (IC/BPS): A systematic review. |
| Q59341080 | Recent advances in imaging and understanding interstitial cystitis |
| Q26773549 | Review of intravesical therapies for bladder pain syndrome/interstitial cystitis |
| Q60918081 | Role of NLRP3 inflammasome in the development of bladder pain syndrome interstitial cystitis |
| Q41478261 | Sacral Neuromodulation for Refractory Bladder Pain Syndrome/Interstitial Cystitis: a Global Systematic Review and Meta-analysis |
| Q48258061 | Sensory mapping of pelvic dermatomes in women with interstitial cystitis/bladder pain syndrome. |
| Q57799018 | Sensory pudendal nerve stimulation increases bladder capacity through sympathetic mechanisms in cyclophosphamide-induced cystitis rats |
| Q26773540 | Similarities between interstitial cystitis/bladder pain syndrome and vulvodynia: implications for patient management |
| Q37367004 | Specific inhibition of ICAM-1 effectively reduces bladder inflammation in a rat model of severe non-bacterial cystitis |
| Q37426010 | Spinal astrocytic activation contributes to mechanical allodynia in a rat model of cyclophosphamide-induced cystitis |
| Q38674296 | Stem Cell Therapy for Interstitial Cystitis/Bladder Pain Syndrome |
| Q47603923 | Stimulators and activators of soluble guanylate cyclase for urogenital disorders |
| Q55041912 | Sub-noxious Intravesical Lipopolysaccharide Triggers Bladder Inflammation and Symptom Onset in A Transgenic Autoimmune Cystitis Model: A MAPP Network Animal Study. |
| Q54203036 | TRPV1 and the MCP-1/CCR2 Axis Modulate Post-UTI Chronic Pain. |
| Q39402568 | The Burden of Bladder Pain in Five European Countries: A Cross-sectional Study |
| Q38939006 | The Challenges of Interstitial Cystitis: Current Status and Future Prospects |
| Q64248348 | The effect of Hydrodistension in combination with Pentosan Polysulfate on treatment outcomes and compliance in the treatment of bladder pain syndrome |
| Q26774274 | The enigma of men with interstitial cystitis/bladder pain syndrome |
| Q91858991 | The misdiagnosis of interstitial cystitis/bladder pain syndrome in a VA population |
| Q90394415 | Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders-From Bench to Bedside |
| Q92924293 | Therapeutic Efficacy of onabotulinumtoxinA Delivered Using Various Approaches in Sensory Bladder Disorder |
| Q92438861 | Therapeutic Endoscopic Treatment Plus Maintenance Dimethyl Sulfoxide Therapy Prolongs Recurrence-Free Time in Patients With Hunner Type Interstitial Cystitis: A Pilot Study |
| Q38785364 | Therapeutic Potential of Human Chorionic Gonadotropin Against Painful Bladder Syndrome/Interstitial Cystitis |
| Q28554395 | Transgenic Mice Expressing MCP-1 by the Urothelium Demonstrate Bladder Hypersensitivity, Pelvic Pain and Voiding Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study |
| Q64098132 | Transplant immunosuppressive drugs in urology |
| Q47417165 | Treatment effectiveness in interstitial cystitis/bladder pain syndrome: Do patient perceptions align with efficacy based guidelines? |
| Q89871173 | Understanding bladder pain syndrome/interstitial cystitis |
| Q37008508 | Urinary Metabolomics Identifies a Molecular Correlate of Interstitial Cystitis/Bladder Pain Syndrome in a Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network Cohort |
| Q26749613 | Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature |
| Q38700131 | Use of Botulinum Toxin in Urologic Diseases |
| Q38679555 | Use of botulinum toxin for voiding dysfunction |
| Q48286220 | Which bladder instillations are more effective? DMSO vs. bupivacaine/heparin/triamcinolone: a retrospective study |
Search more.